Fri, Aug 29, 2014, 9:50 AM EDT - U.S. Markets close in 6 hrs 10 mins


% | $
Quotes you view appear here for quick access.

Biogen Idec Inc. Message Board

  • As_the_world_turns As_the_world_turns Jun 13, 2000 12:57 PM Flag

    Bill R.'s interview was just average

    The CNBC interviewer had all her facts wrong
    about IDEC to start with. Bill R. was quite nervous,
    IMHO. The stock is losing ground after the

    A missed opportunity for us, shareholders. BTW, why
    did Bill mention the Psoriasis drug? I thought that
    the stock tanked after the 1st quarter conference
    call when IDEC mentioned that the Psoriasis drug was
    not found to be effective in preliminary trials.
    Apparently, IDEC is still pursuing this drug. Any info on
    this drug will be appreciated.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • the drug that was discontinued was for SLE and in point of fact it was only discontinued for SLE but a series of PII trials are scheduled to begin in 2000-2001 for other indications.

    • The interview went fairly well, and Dr. Rastetter
      got his points across articulately, if not as
      charismatically as he usually speaks. No traces of a smile
      throughout, even at the beginning and end, when it would have
      been appropriate. What I was dissapointed about was
      the bland laboratory footage of the company. Rather
      than show IDEC's impressive process development and
      manufacturing areas, the labs and techniques could have been
      from any little biotech or even a school. PR needs to
      provide some scenes of outside headquarters, heavy
      equipment and utilities, and gowned cleanroom personnel,

      Bill was braodcast from the conference in Dana Point
      and had to correct Martha on several issues,
      including Genentech's role as IDEC's Rituxan manufacturing
      and marketing partner and Rituxan sales growth. He
      used the opportunities to clarify both, and was
      supported by graphics showing 1999 revenues and 52 week
      stock price. Martha indicated the March-April decline
      was during the sector correction.

      As for
      mention of psoriasis, it was in response to a question
      about IDEC's pipeline. That drug has enormous potential
      for several immune system disorders and I understand
      the company is persuing development in other
      indications despite the preliminary psoriasis results. It
      could still be a blockbuster, IMO.

      IDPH is up
      about 10 points so far today, in a market now reacting
      positively to some comments just made by Alan G. Another
      great day, and the fundamentals and chart continue to
      improve. Long IDPH.

    • William Rastetter is the Chmn./CEO of IDPH. He
      was interviewed today on
      Trials for new drug going nicely, expansion plans in the

341.495+0.255(+0.07%)9:50 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.